

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
March 29, 2016

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Kalvani Bhatt, BS, MS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

David A. Brent, MD

(Chairperson)
Academic Chief
Division of Child Adolescent Psychiatry
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Thomas A. Grieger, MD

Staff Psychiatrist
Maryland Department of Health and Mental Hygiene
Thomas B. Finan Center
Cumberland, Maryland

Dawn F. Ionescu, MD

Depression Clinical and Research Program
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Rajesh Narendran, MD

Associate Professor in Radiology and Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

David Pickar, MD

Adjunct Professor of Psychiatry
Johns Hopkins Medical School
Uniformed Services University of Health Sciences
Gabriel Sciences, LLC
Chevy Chase, Maryland

Kim O. Witzak

(Consumer Representative)
Co-Founder, Executive Director
Woodymatters
Minneapolis, Minnesota

TEMPORARY MEMBERS (Voting)

John E. Duda, MD

Director, Parkinson's Disease Research
Education & Clinical Center
Philadelphia Veteran's Affairs Medical Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Susan Elmore, DVM, MS, DAVCP, DABT

Pathologist and Staff Scientist
National Toxicology Program Pathology Group
Cellular and Molecular Pathology Branch
National Institute of Environmental Health Sciences
National Institutes of Health
Research Triangle Park, North Carolina

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting
March 29, 2016

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Stanley Fahn, MD

H. Houston Merritt Professor of
Neurology/Columbia University
Director Emeritus, Movement Disorder Division
Neurological Institute
New York, New York

Tobias Gerhard, PhD, RPh

Associate Professor
Rutgers University
Department of Pharmacy Practice and
Administration
Ernest Mario School of Pharmacy
New Brunswick, New Jersey

Linda Morgan, MBA, RPh

(Patient Representative)
Asheville, North Carolina

Urmimala Sarakar, MD

Associate Professor in Residence
School of Medicine
University of California, San Francisco
San Francisco, California

Christopher H. Schmid, PhD

Professor of Biostatistics
Center for Evidence Based Medicine
Department of Biostatistics
Brown University School of Public Health
Providence, Rhode Island

Almut Winterstein, RPh, PhD, FISPE

Professor and Interim Chair
Pharmaceutical Outcomes & Policy
College of Pharmacy
Epidemiology, College of Public Health and Health
Professions and College of Medicine
University of Florida
Gainesville, Florida

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Mark Forrest Gordon, MD

Director, Clinical Development and Medical Affairs
General Medicine / Central Nervous Systems &
Established Products
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting
March 29, 2016

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Robert Temple, MD

Deputy Director for Clinical Science
CDER, FDA
Deputy Director (Acting)
Office of Drug Evaluation-I (ODE-I)
Office of New Drugs (OND), CDER, FDA

Mitchell Mathis, MD

Director
Division of Psychiatry Products (DPP)
ODE-I, OND, CDER, FDA

Tiffany R. Farchione, MD

Deputy Director
DPP, ODE-I, OND, CDER, FDA

Marc Stone, MD

Deputy Director of Safety
DPP, ODE-I, OND, CDER, FDA

Paul Andreason, MD

Medical Officer
DPP, ODE-I, OND, CDER, FDA